Granules India spurts as its arm gets USFDA’s nod for Colchicine Tablets

06 Feb 2020 Evaluate

Granules India is currently trading at Rs. 155.40, up by 1.60 points or 1.04% from its previous closing of Rs. 153.80 on the BSE.

The scrip opened at Rs. 153.60 and has touched a high and low of Rs. 161.00 and Rs. 153.35 respectively. So far 4681 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 161.00 on 23-Jan-2020 and a 52 week low of Rs. 84.25 on 26-Jul-2019.

Last one week high and low of the scrip stood at Rs. 162.00 and Rs. 136.75 respectively. The current market cap of the company is Rs. 3910.33 crore.

The promoters holding in the company stood at 42.90%, while Institutions and Non-Institutions held 20.95% and 36.14% respectively.

Granules India’s wholly owned foreign subsidiary -- Granules Pharmaceuticals, Inc., has received approval from US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) for Colchicine Tablets USP, 0.6 mg. It is bioequivalent to the reference listed drug product (RLD), Colcrys Tablets, 0.6 mg, of Takeda Pharmaceuticals USA, Inc. Colchicine Tablets are used for treatment of Familial Mediterranean Fever (FMF).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

605.90 -2.90 (-0.48%)
09-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.10
Dr. Reddys Lab 1371.60
Cipla 1488.15
Lupin 2251.80
Zydus Lifesciences 1009.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.